|
September 2, 2021
|
Caribou Biosciences Provides Business Update and Reports Second Quarter 2021 Financial Results
|
|
|
September 2, 2021
|
Caribou Biosciences Announces Publication of Data Demonstrating High Specificity Genome Editing with its Proprietary chRDNA Technology
|
|
|
September 1, 2021
|
Caribou Biosciences to Participate in Citi’s 16th Annual BioPharma Virtual Conference
|
|
|
August 25, 2021
|
Caribou Biosciences Appoints Nancy Whiting, Pharm.D., to its Board of Directors
|
|
|
July 27, 2021
|
Caribou Biosciences Announces Closing of Upsized Initial Public Offering
|
|
|
July 22, 2021
|
Caribou Biosciences Announces Pricing of Upsized Initial Public Offering
|
|
|
July 12, 2021
|
Caribou Biosciences Announces Dosing of First Patient in Phase 1 Clinical Trial Evaluating CB-010, a CRISPR-Edited Allogeneic Anti-CD19 CAR-T Cell Therapy, in Patients with Relapsed or Refractory B Cell Non-Hodgkin Lymphoma
|
|
|
June 22, 2021
|
Caribou Biosciences Appoints Scott Braunstein, M.D. to Board of Directors
|
|
|
May 17, 2021
|
Caribou Biosciences Announces Appointment of Katy Rezvani, M.D., Ph.D. and Christopher Sturgeon, Ph.D. to its Scientific Advisory Board
|
|
|
May 5, 2021
|
Caribou Biosciences Announces Appointment of Industry Leader Andrew Guggenhime to its Board of Directors
|
|
